YanAn Bicon Pharmaceutical Listed Company

Symbol: 002411.SZ

SHZ

0.62

CNY

Market price today

  • -0.5881

    P/E Ratio

  • 0.0546

    PEG Ratio

  • 950.01M

    MRK Cap

  • 0.00%

    DIV Yield

YanAn Bicon Pharmaceutical Listed Company (002411-SZ) Stock Price & Analysis

Shares Outstanding

1532.28M

Gross Profit Margin

0.15%

Operating Profit Margin

-0.34%

Net Profit Margin

-0.30%

Return on Assets

-0.11%

Return on Equity

-0.25%

Return on Capital Employed

-0.27%

Company general description and statistics

Sector: Basic Materials
Industry: Chemicals
CEO:Mr. Wenxiong Han
Full-time employees:2901
City:Xi'an
Address:Wynn International Finance Center
IPO:2010-05-25
CIK:

YanAn Bicon Pharmaceutical Listed Company researches and develops, produces, and sells pharmaceutical intermediates, pesticide intermediates, and new energy and materials products in China. It offers medical products under the Bikangweizheng and DoctorBaby brands. The company also provides lithium hexafluorophosphate, a material of lithium-ion battery electrolytes for use in cut-resistant gloves, home textile products, cables, fishing nets, outdoor sports wear products, bulletproof helmets, stab-resistant clothing, etc., as well as military industry, aerospace composite materials, ocean-going ships, naval ship ropes, ocean fishing trawls, deep-sea anti-wind wave cages and sporting goods equipment, construction engineering reinforcement, and other high-performance composite materials. In addition, it offers pharmaceutical intermediates, such as triclopyridine sodium, 5,5-dimethylhydantoin, and benzaldehyde. The company was formerly known as JiangSu Bicon Pharmaceutical Listed Company and changed its name to YanAn Bicon Pharmaceutical Listed Company in October 2018. YanAn Bicon Pharmaceutical Listed Company was founded in 2007 and is based in Xi'an, China. YanAn Bicon Pharmaceutical Listed Company was a former subsidiary of Xinyi Bicon New Medicine Industry Complex Investment Co., Ltd.

General Outlook

In simple terms, YanAn Bicon Pharmaceutical Listed Company has 1532.28 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.155% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.342%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.303%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.108% return, is a testament to YanAn Bicon Pharmaceutical Listed Company's adeptness in optimizing resource deployment. YanAn Bicon Pharmaceutical Listed Company's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.250%. Furthermore, the proficiency of YanAn Bicon Pharmaceutical Listed Company in capital utilization is underscored by a remarkable -0.273% return on capital employed.

Stock Prices

YanAn Bicon Pharmaceutical Listed Company's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.95, while its low point bottomed out at $6.71. This variance in figures offers investors a lucid insight into the roller-coaster ride that is YanAn Bicon Pharmaceutical Listed Company's stock market.

Liquidity Ratios

Analyzing 002411.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 74.68% gauges short-term asset coverage for liabilities. The quick ratio (63.83%) assesses immediate liquidity, while the cash ratio (5.92%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio74.68%
Quick Ratio63.83%
Cash Ratio5.92%

Profitability Ratios

002411.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -43.86% underscores its earnings before tax deductions. The effective tax rate stands at 30.85%, revealing its tax efficiency. The net income per EBT, 69.15%, and the EBT per EBIT, 128.21%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -34.21%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-43.86%
Effective Tax Rate30.85%
Net Income per EBT69.15%
EBT per EBIT128.21%
EBIT per Revenue-34.21%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.75, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding64
Days of Inventory Outstanding66
Operating Cycle389.74
Days of Payables Outstanding171
Cash Conversion Cycle218
Receivables Turnover1.13
Payables Turnover2.13
Inventory Turnover5.53
Fixed Asset Turnover1.85
Asset Turnover0.36

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.05, and free cash flow per share, -1.98, depict cash generation on a per-share basis. The cash per share value, 0.37, showcases liquidity position. A payout ratio of -1.16 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -0.30, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-1.05
Free Cash Flow per Share-1.98
Cash per Share0.37
Payout Ratio-1.16
Operating Cash Flow Sales Ratio-0.30
Free Cash Flow to Operating Cash Flow Ratio1.88
Cash Flow Coverage Ratio-0.91
Short Term Coverage Ratio-1.04
Capital Expenditure Coverage Ratio-1.14
Dividend Paid and Capex Coverage Ratio-0.49
Dividend Payout Ratio0.18

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 11.93%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.32, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.97%, and total debt to capitalization, 24.07%, ratios shed light on its capital structure. An interest coverage of -17.66 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio11.93%
Debt Equity Ratio0.32
Long Term Debt to Capitalization3.97%
Total Debt to Capitalization24.07%
Interest Coverage-17.66
Cash Flow to Debt Ratio-0.91
Company Equity Multiplier2.66

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 5.06, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.66, reflects the portion of profit attributed to each share. The book value per share, 3.61, represents the net asset value distributed per share, while the tangible book value per share, 2.51, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share5.06
Net Income Per Share-0.66
Book Value Per Share3.61
Tangible Book Value Per Share2.51
Shareholders Equity Per Share3.61
Interest Debt Per Share1.29
Capex Per Share-0.91

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 5.78%, indicates top-line expansion, while the gross profit growth, -13.61%, reveals profitability trends. EBIT growth, -71.89%, and operating income growth, -71.89%, offer insights into operational profitability progression. The net income growth, -59.88%, showcases bottom-line expansion, and the EPS growth, -53.49%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth5.78%
Gross Profit Growth-13.61%
EBIT Growth-71.89%
Operating Income Growth-71.89%
Net Income Growth-59.88%
EPS Growth-53.49%
EPS Diluted Growth-53.49%
Weighted Average Shares Growth5.09%
Weighted Average Shares Diluted Growth5.09%
Dividends per Share Growth861.28%
Operating Cash Flow Growth386.39%
Free Cash Flow Growth359.71%
10-Year Revenue Growth per Share71.65%
5-Year Revenue Growth per Share44.59%
3-Year Revenue Growth per Share-16.79%
10-Year Operating CF Growth per Share3941.58%
5-Year Operating CF Growth per Share7762.17%
3-Year Operating CF Growth per Share1601.97%
10-Year Net Income Growth per Share-466.11%
5-Year Net Income Growth per Share-213.13%
3-Year Net Income Growth per Share-384.75%
10-Year Shareholders Equity Growth per Share49.48%
5-Year Shareholders Equity Growth per Share-39.13%
3-Year Shareholders Equity Growth per Share-43.78%
10-Year Dividend per Share Growth per Share1859.81%
5-Year Dividend per Share Growth per Share278.09%
3-Year Dividend per Share Growth per Share282.69%
Receivables Growth-25.89%
Inventory Growth-19.45%
Asset Growth-20.63%
Book Value per Share Growth-27.97%
Debt Growth-63.58%
R&D Expense Growth12.11%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 12,047,069,002.36, captures the company's total value, considering both debt and equity. Income quality, -2.77, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 1.82%, highlights investment in innovation. The ratio of intangibles to total assets, 14.44%, indicates the value of non-physical assets, and capex to operating cash flow, -49.67%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value12,047,069,002.36
Income Quality-2.77
Sales General and Administrative to Revenue0.02
Research and Development to Revenue1.82%
Intangibles to Total Assets14.44%
Capex to Operating Cash Flow-49.67%
Capex to Revenue-17.92%
Capex to Depreciation-415.00%
Graham Number7.31
Return on Tangible Assets-8.29%
Graham Net Net-2.60
Working Capital-1,967,118,436
Tangible Asset Value4,017,119,023
Net Current Asset Value-2,623,797,330
Average Receivables5,004,234,878.5
Average Payables1,964,181,221
Average Inventory883,414,291.5
Days Sales Outstanding192
Days Payables Outstanding114
Days of Inventory On Hand47
ROIC2.88%
ROE-0.18%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.17, and the price to book ratio, 0.17, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.18, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.31, and price to operating cash flows, -0.59, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.17
Price to Book Ratio0.17
Price to Sales Ratio0.18
Price Cash Flow Ratio-0.59
Price Earnings to Growth Ratio0.05
Enterprise Value Multiple0.71
Price Fair Value0.17
Price to Operating Cash Flow Ratio-0.59
Price to Free Cash Flows Ratio-0.31
Price to Tangible Book Ratio1.93
Enterprise Value to Sales1.49
Enterprise Value Over EBITDA17.38
EV to Operating Cash Flow4.12
Earnings Yield-9.47%
Free Cash Flow Yield13.22%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of YanAn Bicon Pharmaceutical Listed Company (002411.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.588 in 2024.

What is the ticker symbol of YanAn Bicon Pharmaceutical Listed Company stock?

The ticker symbol of YanAn Bicon Pharmaceutical Listed Company stock is 002411.SZ.

What is company IPO date?

IPO date of YanAn Bicon Pharmaceutical Listed Company is 2010-05-25.

What is company current share price?

Current share price is 0.620 CNY.

What is stock market cap today?

The market cap of stock today is 950013632.000.

What is PEG ratio in 2024?

The current 0.055 is 0.055 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2901.